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$4,297–$4,587) higher; while the median quantile difference was $3,756 (95%CI: 
$3,636–$3,876). The quantile regression differences ranged from a low of $2,078 
(95%CI: $2,012–$2,145) for the 5th quantile to a high of $8,691 (95%CI: $8,395–
$8,987) for the 95th quantile. CONCLUSIONS: Results from econometric regression 
models can vary greatly depending on model assumptions. Quantile regression results 
provide a detailed picture of cost differences across the entire cost distribution, illus-
trating important non-uniformities of differences between groups.
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OBJECTIVES: Electronic data collection is a prominent evolution in the Patient-
Reported Outcomes (PRO) ﬁ eld. Developing translations for e-formats must involve 
a rigorous methodology ensuring conceptual equivalence and cultural relevance across 
languages. Ideally comprehension and acceptability of translations should be tested 
using the actual e-device. For logistical reasons this may be challenging. Alternative 
methods include testing of translations using print outs of screenshots. The translation 
of an Asthma Diary into 20 languages was the opportunity to compare both methods. 
METHODS: (1) Identiﬁ cation of the languages using e-device testing versus those 
using screenshots; (2) comparison of the interview guides used for the respective testing 
methods; and (3) analysis and comparison of the results. RESULTS: A total of 15 
languages were tested on the e-device, 5 with screenshots. The interview guide used 
to test the e-device contained linguistic considerations and questions on instructions 
and use of the device. The interview guide for the screenshots was purely linguistic in 
nature, so as not to confuse respondents with questions about the hypothetical use of 
the e-device. In terms of linguistic observations no differences were seen between the 
e-device and the screenshot testing methods. Feedback on the device usability differed 
by country but also across regions. In most countries/languages observations were 
made around the size of the font/screens and the device instructions. CONCLUSION: 
Testing translations using the actual e-device not only provides comprehensive feed-
back on the language of the items, but also information on the practical use of the 
device, and the interaction of both in the context of each country. Screenshot testing 
can be considered an alternative in cases where e-device testing is difﬁ cult.
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BACKGROUND: The EXACT (Exacerbations of COPD Tool) is a daily diary used 
in clinical trials to evaluate frequency, severity, and duration of COPD exacerbations. 
Reporting utilities from the EXACT allows a more accurate account of preference 
change for economic evaluations than current methods. Multi-attribute utility theory 
(MAUT) employs a series of equations to develop a function (MAUF) to report utili-
ties. OBJECTIVES: To develop and validate an MAUF to estimate utilities from the 
EXACT for use in UK cost-effectiveness studies. METHODS: EXACT-U is comprised 
of 5 items with 3–5 levels each. Items and levels were grouped to form mixed-level 
and corner health states. Development group was used for MAUF construction; sepa-
rate Validation group was used to test functions. UK general public respondents valued 
11 health states (including best/worst) using TTO from full health/dead over 10 years. 
MAUF used the multiplicative model by: (1)-Calculating mean utility of each attribute 
level; (2)- Calculating group disutilities for each level; (3)-Applying multiplicative 
model to derive disutility function; and (4)-Converting disutility function to utility 
function. Performance assessed by: number of inconsistencies predicted, mean absolute 
error (MAE), and root mean squared error (RMSE). Models validated using a second-
ary analysis of a separate data set of EXACT patient data to test discriminant validity 
(statistical signiﬁ cance) and responsiveness (standardized response mean (SRM)). 
RESULTS: TTO interviews conducted with 400 respondents: 350 Development 
group, 50 Validation group. Respondents were: 36 yrs old (13.5 SD), 39.2% male, 
and 46.4% White British. MAUF reported MAE = 0.032, and RMSE = 0.170. Dis-
criminant validity supported by utility differences by clinical severity: stable/acute (P 
= 0.001); mild/moderate (p = 0.01); moderate/severe (p = 0.0001); and severe/very 
severe (P = 0.14). Responsiveness by SRM was 0.52 (Day 3), 0.55 (Day 7), 0.66 (Day 
10), and 0.76 (Day 13). CONCLUSIONS: The EXACT-U is a condition-speciﬁ c 
preference-based measure to report COPD exacerbation utilities with minimal error, 
good discrimination, and good responsiveness.
PRS51
ADVANCED PATTERN RECOGNITION METHODS FOR PREDICTING 
TREATMENT RESPONSE IN PATIENTS SUFFERING FROM ALLERGIC 
RHINITIS
Krajewski J, Koeberlein J
University of Wuppertal, Wuppertal, Germany
OBJECTIVES: The aim of the present analysis was to optimize the prediction of 
treatment response in patients with allergic rhinitis. To determine an optimal predic-
tion accuracy, we used different Pattern Recognition (PR) approaches and evaluated 
their added value compared to standard predictive models as Logistic Regression, and 
Linear Discriminant Analysis. METHODS: In order to optimize the prediction of 
treatment response, 76,981 case reports of patient with allergic rhinitis from ten post-
marketing-studies in Germany were analyzed by means of PR methodology. The 
processing steps applied within this study are: (a) feature extraction (genetic algorithm 
based synthetic feature calculation), (b) dimensionality reduction (correlation ﬁ lter 
based feature selection, wrapper based feature selection, Principle Component Analy-
sis based feature transformation), (c) classiﬁ cation (Support Vector Machine, Decision 
Tree, K-Nearest Neighbor, Random Forest, Artiﬁ cial Neural Network, Bagging, 
Boosting Logistic Regression, Linear Discriminant Analysis), and (d) validation (leave-
one-sample-out cross validation). RESULTS: The AdaBoost Support Vector Machine 
classiﬁ er with correlation ﬁ lter based feature selection achieved the highest unweighted 
mean recall rate (mean of sensitivity and speciﬁ city; URR) of 62.8%. The standard 
Logistic Regression approach yielded 50.4% (−12.4%), the Linear Discriminant 
Analysis 50.6% (−12.6%). CONCLUSIONS: In comparison to standard learning 
schemes as e.g. Logistic Regression, and Linear Discriminant Analysis applying 
advanced PR methods improves substantially the prediction of treatment response in 
patients with allergic rhinitis. Due to the achieved added value and the superiority of 
Pattern Recognition methods within several benchmarking studies, advanced PR 
methods should be primarily considered for modeling and prediction tasks within the 
ﬁ eld of pharmacoeconomics. 
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OBJECTIVES: Although a number of guidelines are available for the reporting of 
clinical trials and interventional studies, there is limited consensus in the structure, 
content and terminology associated with reporting of prospective non-interventional 
observational studies. The objective of this study was to describe best practices in 
reporting of observational studies based on a review of relevant guidelines for report-
ing data from clinical studies. METHODS: A systematic literature review was con-
ducted and six relevant guidelines that could be adapted for reporting of results from 
prospective non-interventional observational studies were identiﬁ ed. The guidelines 
reviewed included the FDA guideline for abbreviated clinical study reports (CSR), the 
EMEA guideline for CSR, the International Conference on Harmonization (ICH) E3 
guideline for CSR, Consolidated Standards of Reporting Trials (CONSORT) guideline 
for pragmatic trials, the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guideline and the International Society for Pharmacoepide-
miology (ISPE) guideline for safety reports. The structure, content, and terminology 
used in the reporting template recommended by the various guidelines were analyzed. 
RESULTS: There were substantial differences in the structure, content and terminol-
ogy recommended by the six guidelines. For example, in contrast to all other guide-
lines, the CONSORT guidelines mention “Objectives” under “Methods” instead of 
“ ‘Introduction.” Under the Results section, for reporting of unadjusted and adjusted 
estimates from outcomes data, the STROBE guideline recommends its inclusion within 
the Main Results section, whereas the CONSORT guideline recommends its inclusion 
within the Outcomes and Estimation section. Some guidelines, especially those focus-
ing on interventional studies, were more similar in content. CONCLUSIONS: Based 
on the evaluation of similarities and differences in the guidelines, we propose a struc-
ture and template for reporting of prospective non-interventional observational 
studies. Recommendations are also provided for adapting the proposed template based 
on study objectives and design.
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OBJECTIVES: Increasingly, innovative oncology drugs are licensed in settings where 
randomised controlled trials (RCTs) are ethically and/or practically infeasible. The 
